Japanese company profile · 4503

Astellas Pharma Inc.

Official English company name published by the issuer.

Original Japanese company name: アステラス製薬株式会社

Name follows the issuer's official English company information. English company name source

FY2025 · fiscal year ended March 2026Latest filing date: 2026-06-16

What does this company do?

What does this company do?

In its FY2025 public filing, Astellas Pharma Inc. reports Research and development, manufacture and sale of pharmaceuticals. The page shows business-level revenue and profit where the source disclosures support comparison.

Astellas Pharma Inc.'s largest reported business by revenue in FY2025 was Research and development, manufacture and sale of pharmaceuticals.

The business with the highest reported segment profit in FY2025 was Research and development, manufacture and sale of pharmaceuticals.

FY2025 · fiscal year ended March 2026 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥2.14T ↗
FY2025 · fiscal year ended March 2026
Operating profit
¥382.63B ↗
FY2025 · fiscal year ended March 2026
Comparable margin
17.9% ↗
FY2025 · fiscal year ended March 2026

IFRS · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
4503
EDINET code
E00920
Corporate number
5010001034966
Listing status
Listed
Industry (EDINET filer classification)
Pharmaceuticals

Location and fiscal year

Headquarters
東京都中央区 · As filed in Japanese
Fiscal year end
3month
Latest fiscal year
FY2025
Accounting standard
IFRS
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
14,099 people (FY2025)
Employees (non-consolidated)
4,081 people (FY2025)
Capital stock
JPY 103.0 billion (FY2025)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

Revenue leader and profit leader

Research and development, manufacture and sale of pharmaceuticals

FY2025 · fiscal year ended March 2026 · Business Segment revenue Segment profit (loss)
BusinessSegment revenueShare of company salesSegment profit (loss)Margin
Research and development, manufacture and sale of pharmaceuticals¥2.14T ↗—¥382.63B ↗17.9%

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

IFRS · Consolidated
  1. FY202160.6¥1.3T
  2. FY202271.0¥1.52T
  3. FY202375.0¥1.6T
  4. FY202489.4¥1.91T
  5. FY2025100.0¥2.14T

Company operating profit

IFRS · Consolidated
  1. FY202140.7¥155.69B
  2. FY202234.8¥133.03B
  3. FY20236.7¥25.52B
  4. FY202410.7¥41.04B
  5. FY2025100.0¥382.63B

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

Reported Segment revenue by business over time

Reported Segment revenue by business over time

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Research and development, manufacture and sale of pharmaceuticals¥1.3T¥1.52T¥1.6T¥1.91T¥2.14T

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth82
    Position among all companies with available values in the fixed reference data.FY2021→FY2025
  • Profitability92
    Position among all companies with available values in the fixed reference data.FY2025
  • Business concentration—
    No comparable data
  • Business change—
    No comparable data
  • Cash generation—
    No comparable data
  • Growth persistence79
    Peer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024, FY2024→FY2025

Next

Ask about this company

Source

Public filing

FY2025 · fiscal year ended March 2026

The source document may be in Japanese.

Filing ID: S100YBPK

View original filing ↗

根拠となる資料